Deoxyribonucleic acid within the Stereotactic Ablative Radiotherapy field (DNA (SABR field))

Deoxyribonucleic acid (DNA) within the tumor and its associated stroma serves as the primary biological substrate for Stereotactic Ablative Radiotherapy (SABR), also known as Stereotactic Body Radiation Therapy (SBRT). SABR delivers highly concentrated, ablative doses of ionizing radiation to a precise anatomical volume, causing lethal damage to the genomic integrity of both malignant cells and the supporting stromal microenvironment (Hall & Giaccia, 2018). The therapeutic efficacy of this approach relies on the induction of complex DNA double-strand breaks (DSBs) that exceed the repair capacity of the targeted cells, leading to senescence or programmed cell death (PubMed: 28103442). Beyond direct cytotoxicity, damage to stromal DNA can disrupt the tumor-supportive vasculature and trigger an immunogenic response, potentially contributing to systemic anti-tumor effects (NIH: PMC5504668). While DNA is a universal molecule rather than a specific protein receptor, it is the functional target for radiosensitizing drugs and DNA damage response (DDR) inhibitors, such as PARP inhibitors, which aim to exacerbate the effects of radiation (PubMed: 30655208). Monitoring the degradation and clearance of this DNA is a key component in assessing clinical response and treatment-related toxicity.

Other names

Tumor and stromal DNASBRT-targeted genomic DNAIntratumoral DNARadiation-targeted DNA

Ionizing radiation induces direct and indirect (via reactive oxygen species) DNA damage, specifically complex double-strand breaks (DSBs), which lead to cell cycle arrest, mitotic catastrophe, and apoptosis in both tumor and stromal cells.